Results 41 to 50 of about 174,356 (352)
GENETIC POLYMORPHISM OF RETROPERITONEAL MYXOID LIPOSARCOMA
Сибирский онкологический журнал, 2020 Objective: to detect new molecular genetic markers and therapeutic targets in retroperitoneal myxoid liposarcoma.Material and Methods. DNA samples isolated from tumor tissue and obtained from formalinfixed paraffin-embedded (FFPE) slides were used.
A. Yu. Volkov +4 more
doaj +1 more source
Basrah Journal of Surgery, 2023 Background Papillary thyroid carcinoma is the most common endocrine and thyroid malignancy. The (BRAF V600E) mutation is the most common mutation in papillary thyroid cancer (PTC). The mutation is detected in about (60%) of the cases.
Sarah Ali Darweesh +3 more
doaj +1 more source
The melanoma-specific graded prognostic assessment does not adequately discriminate prognosis in a modern population with brain metastases from malignant melanoma [PDF]
, 2015 The melanoma-specific graded prognostic assessment (msGPA) assigns patients with brain metastases from malignant melanoma to 1 of 4 prognostic groups.
A Likhacheva +36 more
core +2 more sources
The newfound relationship between extrachromosomal DNAs and excised signal circles
FEBS Letters, EarlyView.Extrachromosomal DNAs (ecDNAs) contribute to the progression of many human cancers. In addition, circular DNA by‐products of V(D)J recombination, excised signal circles (ESCs), have roles in cancer progression but have largely been overlooked. In this Review, we explore the roles of ecDNAs and ESCs in cancer development, and highlight why these ...
Dylan Casey, Zeqian Gao, Joan Boyes
wiley +1 more source
Endocrine ConnectionsNext-generation sequencing (NGS) is of great benefit to clinical practice in terms of identifying genetic alterations. This study aims to clarify the gene background and its influence on thyroid tumors in the Chinese population.
Xu-Feng Chen +6 more
doaj +1 more source
Response and Resistance to Paradox-Breaking BRAF Inhibitor in Melanomas [PDF]
, 2018 FDA-approved BRAF inhibitors produce high response rates and improve overall survival in patients with BRAF V600E/K-mutant melanoma, but are linked to pathologies associated with paradoxical ERK1/2 activation in wild-type BRAF cells.
Aplin, Andrew E. +10 more
core +1 more source
BRAF Inhibitors in BRAF-Mutated Colorectal Cancer: A Systematic Review
Journal of Clinical Medicine, 2023 Colorectal cancer (CRC) is the second-leading cause of cancer-related deaths globally. BRAF mutation is present in about 10% of CRC patients and is associated with a poor response to chemotherapy. These patients have a relatively poor prognosis. This review aims to assess the efficacy and safety of BRAF inhibitors in BRAF-mutated CRC patients.
Wajeeha Aiman +13 more
openaire +2 more sources
Molecular Oncology, EarlyView.A‐to‐I editing of miRNAs, particularly miR‐200b‐3p, contributes to HGSOC progression by enhancing cancer cell proliferation, migration and 3D growth. The edited form is linked to poorer patient survival and the identification of novel molecular targets.
Magdalena Niemira +14 more
wiley +1 more source
European Thyroid JournalObjective: The aim was to evaluate the possible association between some endocrine disruptive chemicals and thyroid cancer (TC) in an Italian case–control cohort.
Valentina Cirello +9 more
doaj +1 more source
Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAFV600E targeted inhibition in a novel syngeneic murine glioma model. [PDF]
, 2016 Inhibitors of BRAFV600E kinase are currently under investigations in preclinical and clinical studies involving BRAFV600E glioma. Studies demonstrated clinical response to such individualized therapy in the majority of patients whereas in some patients ...
Berger, Mitchel S +12 more
core +1 more source